Literature DB >> 20805291

Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease.

Rhiannon N Hardwick1, Craig D Fisher, Mark J Canet, April D Lake, Nathan J Cherrington.   

Abstract

Nonalcoholic fatty liver disease (NAFLD), which occurs in approximately 17 to 40% of Americans, encompasses progressive stages of liver damage ranging from steatosis to nonalcoholic steatohepatitis (NASH). Inflammation and oxidative stress are known characteristics of NAFLD; however, the precise mechanisms occurring during disease progression remain unclear. The purpose of the current study was to determine whether the expression or function of enzymes involved in the antioxidant response, NAD(P)H:quinone oxidoreductase 1 (NQO1), glutathione transferase (GST), and glutamate cysteine ligase, are altered in the progression of human NAFLD. Human livers staged as normal, steatotic, NASH (fatty), and NASH (not fatty) were obtained from the Liver Tissue Cell Distribution System. NQO1 mRNA, protein, and activity tended to increase with disease progression. mRNA levels of the GST isoforms A1, A2, A4, M3, and P1 increased with NAFLD progression. Likewise, GST A and P protein increased with progression; however, GST M protein levels tended to decrease. Of interest, total GST activity toward the substrate 1-chloro-2,4-dinitrobenzene decreased with NAFLD progression. GSH synthesis does not seem to be significantly dysregulated in NAFLD progression; however, the GSH/oxidized glutathione redox ratio seemed to be reduced with disease severity, indicating the presence of oxidative stress and depletion of GSH throughout progression of NAFLD. Malondialdehyde concentrations were significantly increased with disease progression, further indicating the presence of oxidative stress. Nuclear immunohistochemical staining of nuclear factor E2-related factor 2 (Nrf2), an indicator of activation of the transcription factor, was evident in all stages of NAFLD. The current data suggest that Nrf2 activation occurs in response to disease progression followed by induction of specific Nrf2 targets, whereas functionality of specific antioxidant defense enzymes seems to be impaired as NAFLD progresses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20805291      PMCID: PMC2993454          DOI: 10.1124/dmd.110.035006

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  36 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

Review 2.  Nuclear receptor-mediated transcriptional regulation in Phase I, II, and III xenobiotic metabolizing systems.

Authors:  Kotoko Nakata; Yoshitomo Tanaka; Tatsuya Nakano; Tatsuhiko Adachi; Hiroshi Tanaka; Tsuguchika Kaminuma; Toshihisa Ishikawa
Journal:  Drug Metab Pharmacokinet       Date:  2006-12       Impact factor: 3.614

3.  Transcriptional regulation of the antioxidant response element. Activation by Nrf2 and repression by MafK.

Authors:  T Nguyen; H C Huang; C B Pickett
Journal:  J Biol Chem       Date:  2000-05-19       Impact factor: 5.157

Review 4.  Pathophysiology of nonalcoholic steatohepatitis.

Authors:  Arthur J McCullough
Journal:  J Clin Gastroenterol       Date:  2006-03       Impact factor: 3.062

5.  Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis.

Authors:  Craig D Fisher; Jonathan P Jackson; Andrew J Lickteig; Lisa M Augustine; Nathan J Cherrington
Journal:  Arch Toxicol       Date:  2008-05-17       Impact factor: 5.153

6.  Glutathione S-transferase T1- and M1-null genotypes and coronary artery disease risk in patients with Type 2 diabetes mellitus.

Authors:  Samantha Manfredi; Debora Calvi; Martina del Fiandra; Nicoletta Botto; Andrea Biagini; Maria Grazia Andreassi
Journal:  Pharmacogenomics       Date:  2009-01       Impact factor: 2.533

Review 7.  Regulatory mechanism of glutathione S-transferase P-form during chemical hepatocarcinogenesis: old wine in a new bottle.

Authors:  Ken Higashi; Hiroshi Hiai; Taneaki Higashi; Masami Muramatsu
Journal:  Cancer Lett       Date:  2004-06-25       Impact factor: 8.679

Review 8.  Glutathione S-transferases--biomarkers of cancer risk and chemopreventive response.

Authors:  M L Clapper; C E Szarka
Journal:  Chem Biol Interact       Date:  1998-04-24       Impact factor: 5.192

Review 9.  Analysis of glutathione: implication in redox and detoxification.

Authors:  Anna Pastore; Giorgio Federici; Enrico Bertini; Fiorella Piemonte
Journal:  Clin Chim Acta       Date:  2003-07-01       Impact factor: 3.786

10.  Global analysis of protein damage by the lipid electrophile 4-hydroxy-2-nonenal.

Authors:  Simona G Codreanu; Bing Zhang; Scott M Sobecki; Dean D Billheimer; Daniel C Liebler
Journal:  Mol Cell Proteomics       Date:  2008-12-02       Impact factor: 5.911

View more
  78 in total

1.  Establishment of a mouse model of enalapril-induced liver injury and investigation of the pathogenesis.

Authors:  Yuji Shirai; Shingo Oda; Sayaka Makino; Koichi Tsuneyama; Tsuyoshi Yokoi
Journal:  Lab Invest       Date:  2017-03-06       Impact factor: 5.662

2.  Impact of Nonalcoholic Fatty Liver Disease on Toxicokinetics of Tetrachloroethylene in Mice.

Authors:  Joseph A Cichocki; Shinji Furuya; Kranti Konganti; Yu-Syuan Luo; Thomas J McDonald; Yasuhiro Iwata; Weihsueh A Chiu; David W Threadgill; Igor P Pogribny; Ivan Rusyn
Journal:  J Pharmacol Exp Ther       Date:  2017-02-01       Impact factor: 4.030

Review 3.  Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis.

Authors:  Mark J Canet; Nathan J Cherrington
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-07-03       Impact factor: 4.481

Review 4.  Effects of red wine on postprandial stress: potential implication in non-alcoholic fatty liver disease development.

Authors:  Ilaria Peluso; Husseen Manafikhi; Raffaella Reggi; Maura Palmery
Journal:  Eur J Nutr       Date:  2015-03-16       Impact factor: 5.614

5.  Parameterization of Microsomal and Cytosolic Scaling Factors: Methodological and Biological Considerations for Scalar Derivation and Validation.

Authors:  Michael J Doerksen; Robert S Jones; Michael W H Coughtrie; Abby C Collier
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-12-19       Impact factor: 2.441

6.  Tyrosol Attenuates High Fat Diet-Induced Hepatic Oxidative Stress: Potential Involvement of Cystathionine β-Synthase and Cystathionine γ-Lyase.

Authors:  Lindsei K Sarna; Victoria Sid; Pengqi Wang; Yaw L Siow; James D House; Karmin O
Journal:  Lipids       Date:  2015-10-30       Impact factor: 1.880

7.  The adaptive endoplasmic reticulum stress response to lipotoxicity in progressive human nonalcoholic fatty liver disease.

Authors:  April D Lake; Petr Novak; Rhiannon N Hardwick; Brieanna Flores-Keown; Fei Zhao; Walter T Klimecki; Nathan J Cherrington
Journal:  Toxicol Sci       Date:  2013-10-04       Impact factor: 4.849

Review 8.  Reactive oxygen and nitrogen species in steatotic hepatocytes: a molecular perspective on the pathophysiology of ischemia-reperfusion injury in the fatty liver.

Authors:  Megan J Reiniers; Rowan F van Golen; Thomas M van Gulik; Michal Heger
Journal:  Antioxid Redox Signal       Date:  2014-02-19       Impact factor: 8.401

9.  Glial cell response to 3,4-(+/-)-methylenedioxymethamphetamine and its metabolites.

Authors:  Joseph M Herndon; Aram B Cholanians; Serrine S Lau; Terrence J Monks
Journal:  Toxicol Sci       Date:  2013-12-03       Impact factor: 4.849

Review 10.  Vitamin E and nonalcoholic fatty liver disease.

Authors:  Tommy Pacana; Arun J Sanyal
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2012-11       Impact factor: 4.294

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.